Union Bancaire Privee UBP SA Makes New Investment in ARK Genomic Revolution ETF (BATS:ARKG)

Union Bancaire Privee UBP SA acquired a new stake in shares of ARK Genomic Revolution ETF (BATS:ARKG) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,910 shares of the company’s stock, valued at approximately $45,000.

A number of other institutional investors and hedge funds have also made changes to their positions in ARKG. JPMorgan Chase & Co. increased its stake in ARK Genomic Revolution ETF by 31.0% during the third quarter. JPMorgan Chase & Co. now owns 2,955,279 shares of the company’s stock worth $75,655,000 after acquiring an additional 698,701 shares during the last quarter. Atom Investors LP raised its holdings in ARK Genomic Revolution ETF by 15.2% in the third quarter. Atom Investors LP now owns 49,131 shares of the company’s stock valued at $1,258,000 after buying an additional 6,496 shares during the period. Barclays PLC lifted its position in ARK Genomic Revolution ETF by 252.7% during the third quarter. Barclays PLC now owns 285,108 shares of the company’s stock valued at $7,299,000 after buying an additional 204,283 shares in the last quarter. Elmwood Wealth Management Inc. grew its stake in ARK Genomic Revolution ETF by 39.7% during the third quarter. Elmwood Wealth Management Inc. now owns 57,766 shares of the company’s stock worth $1,479,000 after buying an additional 16,412 shares during the period. Finally, National Bank of Canada FI increased its position in shares of ARK Genomic Revolution ETF by 28.4% in the third quarter. National Bank of Canada FI now owns 4,155 shares of the company’s stock worth $106,000 after acquiring an additional 920 shares in the last quarter.

ARK Genomic Revolution ETF Trading Up 11.2 %

BATS:ARKG opened at $26.26 on Thursday. The company’s fifty day simple moving average is $25.10 and its two-hundred day simple moving average is $25.18.

About ARK Genomic Revolution ETF

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.